COMPANY RESEARCHKymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Kymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| SAR447971 / KT-485 | IRAK4 · See individual trial / indication; not individually confirmed in this review | Phase 1 | Clinical entry; complete human results not confirmed by this source |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Nurix said Sanofi will stop the first-in-human Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix no longer expects future milestone payments or royalties from this asset, while other licensed programs remain eligible for such payments. The November 3 announcement did not disclose the reason for discontinuation.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
